CD36 and familial pancreatic carcinoma: Further studies are needed to gain insight into the concomitant impact of CD36 and CD97 on modulating fibroblasts phenotypes under different conditions [95], thus offering potential innovative therapeutic strategies to inactivate CAF and prevent aberrant tumor-stroma crosstalk in pancreatic cancer.